Plexin-A4 Mediates Cytotoxic T-cell Trafficking and Exclusion in Cancer

Area of Science:

• Immunology
• Cancer Biology
• Molecular Biology

Background:

• Cytotoxic T cell (CTL) infiltration is crucial for limiting cancer progression but is often hindered by the immunosuppressive tumor microenvironment, impacting immunotherapy efficacy.
• The axon guidance molecule Plexin-A4 (Plxna4) is expressed in CTLs and its levels change during tumor entry.

Purpose of the Study:

• To investigate the role of Plexin-A4 (Plxna4) in regulating cytotoxic T cell (CTL) function and anti-tumor immunity.
• To explore the therapeutic potential of targeting Plxna4 in cancer immunotherapy, particularly in melanoma.

Main Methods:

• Deletion of Plxna4 in CTLs and in mouse models (stromal and hematopoietic).
• Assessment of CTL homing, proliferation, and anti-tumor activity.
• Adoptive transfer of Plxna4-deficient CTLs in a melanoma model.
• Analysis of Plxna4 expression in circulating CTLs from melanoma patients undergoing immunotherapy.

Main Results:

• Plxna4 deletion in CTLs enhanced their homing to lymph nodes and tumors, increased proliferation via Rac1 activation, and improved anti-tumor immunity.
• Mice with Plxna4 deletion showed enhanced CTL infiltration and reduced tumor growth.
• Adoptive transfer of Plxna4-deficient CTLs improved survival and therapeutic outcomes in melanoma models, especially when combined with anti-PD-1 therapy.
• Elevated Plxna4 in circulating CTLs of melanoma patients decreased upon successful anti-PD-1/anti-CTLA-4 treatment.

Conclusions:

• Plxna4 acts as a cell-autonomous checkpoint inhibiting CTL migration and proliferation.
• Targeting Plxna4 presents a novel strategy for enhancing CTL-based immunotherapies.
• Plxna4 levels in circulating CTLs may serve as a predictive biomarker for response to immune checkpoint blockade in melanoma.